Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-966-0 | CAS number: 101-68-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: The study falls short of highest standards concerning aspects of protocol or reporting. Acceptable literature publication based on full study report . Also poster presentation with minimal description of method and report
Data source
Referenceopen allclose all
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 996
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 994
- Reference Type:
- publication
- Title:
- Untersuchungen zur chronischen Toxizität/Kanzerogenität von 4,4'-Methylendiphenyl-Diisocyanat (MDI). Band 1 - 3
- Author:
- Hoymann HG, Buschmann J, Heinrich U & Bartsch W
- Year:
- 1 995
- Bibliographic source:
- Fraunhofer-Institut für Toxikologie und Aerosolforschung, Forschungsbericht 116 06 084
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- not specified
Test material
- Reference substance name:
- 4,4'-methylenediphenyl diisocyanate
- EC Number:
- 202-966-0
- EC Name:
- 4,4'-methylenediphenyl diisocyanate
- Cas Number:
- 101-68-8
- Molecular formula:
- C15H10N2O2
- IUPAC Name:
- 1-isocyanato-4-[(4-isocyanatophenyl)methyl]benzene
- Reference substance name:
- benzene, 1,1'- methylenebis[4-isocyanato-
- IUPAC Name:
- benzene, 1,1'- methylenebis[4-isocyanato-
- Details on test material:
- SOURCE: Bayer A.G. Leverkusen
PURITY: no data ; 4,4'- MDI (Desmodur 44 M Schuppen)
ANY OTHER INFORMATION: no data
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- other: Wistar Crl: (WI)BR
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Wiga, Germany
- Age at study initiation: No data
- Weight at study initiation: No data
- Fasting period before study: No data
- Housing: The rats were housed prior to conception in groups of two, and thereafter individually in cages with softwood bedding.
- Diet (e.g. ad libitum): Altromin 1314 N
- Water (e.g. ad libitum): tap water, ad libitum
- Acclimation period: No data
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 24 + 2°C
- Humidity (%):40-70%
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): The light intensity was 150 lux (600 lux with additional light for working procedures).
IN-LIFE DATES: No data
Administration / exposure
- Route of administration:
- inhalation
- Type of inhalation exposure (if applicable):
- whole body
- Vehicle:
- other: yes, exposed in inhalation chambers to fresh air only.
- Details on exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: Exposure chamber
- Method of holding animals in test chamber: Animals were exposed by whole-body inhalation in inhalation chambers.
- System of generating particulates/aerosols: The MDI aerosol was generated using an evaporation condensation technique consisting of the following steps: atomisation of the liquidised MDI, complete evaporation of the droplets, and recondensation of the gaseous MDI by turbulent mixing with dilution air.
- Temperature, humidity, pressure in air chamber: No data
- Method of particle size determination: The aerosol in the exposure chambers was monitored continuously by means of light-scattering photometers, and a "Bemer" low-pressure impactor was used for the determination of the size distribution of the MDI aerosol.
TEST ATMOSPHERE
- Brief description of analytical method used: A technique (no details given) for sample collection and analysis of MDI in both particle and gas forms which guaranteed effective and continuous monitoring of the exposure atmosphere was applied.
- Samples taken from breathing zone: no data
VEHICLE (if applicable)
- Composition of vehicle: Clean air - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The MDI aerosol in the exposure chambers was monitored continuously by means of light-scattering photometers, and a "Bemer" low-pressure impactor was used for the determination of the size distribution of the MDI aerosol. A technique for sample collection and analysis of MDI in both particle and gas forms which guaranteed effective and continuous monitoring of the exposure atmosphere was applied.
- Details on mating procedure:
- - Impregnation procedure: cohoused
- If cohoused:
- M/F ratio per cage: 1:1
- Length of cohabitation: Overnight
- Proof of pregnancy: vaginal smear was considered p.c. 0 (post conception). - Duration of treatment / exposure:
- 10 days during gestational days 6 to 15
- Frequency of treatment:
- once daily; 6h a day
- Duration of test:
- 6 to 15 post conception (p.c.); 5 days post-treatment without exposure
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 1, 3 and 9 mg/m3
Basis:
other: actual weekly concs
- No. of animals per sex per dose:
- 26 inseminated females per group
- Control animals:
- other: yes, exposed in inhalation chambers to fresh air only
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: No data
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: No data
BODY WEIGHT: Yes
- Time schedule for examinations: pc 1, 6 -15 and 20.
FOOD CONSUMPTION: Yes
- Food consumption: on days 6, 10, 15 and 20 p.c.
WATER CONSUMPTION: No data
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice: on p.c. 20
- Organs examined: Number of corporea lutea, implantation sites, live and dead fetuses, early and late resorptions, pre- and postimplantation loss, and fetal and placental weights. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: No
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: pre- and postimplantation loss, and fetal and placental weights. - Fetal examinations:
- - External examinations: Yes: all foetuses were thoroughly examined for gross anomalies
- Soft tissue examinations: Yes: visceral anomalies
- Skeletal examinations: Yes: half of the foetuses for skeletal anomalies and the degree of ossification after bone staining with alizarin red.
- Head examinations: No data - Statistics:
- Parametric data: ANOVA and subsequent two-tailed Dunnett's test with the dam/litter as unit. Incidences: two-tailed Fisher's exact test based on both litters and fetuses. Mean values, standard deviations and sample sizes were calculated and tabled. Incidences were alternatively shown as number of fetuses affected/number of litters with affected fetuses. Differences were considered significant at p<0.05 (*) or 0.01 (**).
- Indices:
- No data.
- Historical control data:
- No data.
Results and discussion
Results: maternal animals
Maternal developmental toxicity
- Details on maternal toxic effects:
- Maternal toxic effects:no effects
Details on maternal toxic effects:
MATERNAL TOXICITY EFFECTS BY DOSE LEVEL:
Mortality and day of death: no mortalities, no other clinical symptoms in the dams
Body weights: no effect on body weight gain.
Food consumption: decreased in all treated groups during exposure, with statistically significance from day 6 to 10 p.c. in the high and mid dose group and from day 10 to 15 p.c. in all treated groups. Food consumption returned to normal after exposure ceased.
At necropsy: no treatment-related effects, however
Absolute and relative lung weights: statistically significant increased in the top dose (parameter not investigated in the low- and mid-conc groups).
Reproductive data: 1/26 animal of the control group and 2/25 of the high-conc group were not pregnant. Nr of copora lutea, implantation sites, pre- and post implantation loss, fetal and placental weights, gross and visceral anomalies, degree of ossification and life fetuses per dam: no statistically significant differences between the groups.
Dose level (mg/m3): 0/ 1/ 3/ 9
No of mated dams: 26/ 26/ 25/ 25
No of gravid females: 25/ 26/ 25/ 23
No of corpora lutea: 19.4 (2.6)/ 18.9 (3.6)/ 19.1 (2.3)/ 19.9 (3.2)
No of implantation sites (mean +/- SE): 17.8 (1.5)/ 17.0 (2.1)/ 17.3 (3.6)/ 16.7 (2.3)
No of live foetuses per dam (mean +/- SE): 17.0 (1.6)/ 16.0 (2.1)/ 16.1 (3.6)/ 16.7 (2.3)
No of postimplantation losses (mean +/- SE): 0.9 (0.9)/ 1.0 (1.2)/ 1.2 (1.4)/ 0.7 (0.7)
Placental weights (mean +/- SE): 0.57 (0.05)/ 0.59 (0.05)/ 0.60 (0.08)/ 0.58 (0.06)
Effect levels (maternal animals)
open allclose all
- Key result
- Dose descriptor:
- LOAEC
- Effect level:
- <= 9 mg/m³ air
- Basis for effect level:
- organ weights and organ / body weight ratios
- other: Lung
- Remarks on result:
- other: 6h/day exposure (days 6-15 p.c.)
- Remarks:
- Lung weights not recorded in mid and low-dose groups
- Dose descriptor:
- other: LOAEL embryo/fetotoxicity
- Effect level:
- 9 mg/m³ air
- Basis for effect level:
- other: effect type not specified
Results (fetuses)
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
Weight of live fetuses: a) males: comparable in all groups; b) females: comparable in all groups
Sex ratio: no significant difference
Gross anomalies (No of fetuses/ No of litters): no significant difference.
Details:
Total No investigated: 424/25; 415/26; 403/25; 385/23
Subcutaneous hemorrhages: 5/5; 5/5; 9/8; 7/6
Cyanosis: 0; 2/1; 0; 0
Runt: 0; 0; 0; 1/1
Total anomalies: 5/5; 7/6; 9/8; 8/7
Visceral anomalies (investigated: unilateral shortened incisor, asymmetric thymus, dilated renal pelvis, dilated ureter, blood in resp. tract, blood in peritoneum, free blood in brain, stomach, ocular region, renal pelvis, ureter, pericardium, thoracic cavity, subcutaneous hemorrhages on 203; 200; 193 and 186 fetuses): no relevant significant differences.
Slight dilatation of renal pelvis: low dose group: significantly increased number of fetuses with this anomaly (within the limits of biological variability of the strain; no dose-response relationship; not statistically different if comparison on a per litter base)
Degree of ossification: no relevant significant difference (exposure groups display decrease in incomplete or missing ossification).
Incomplete ossification of nasal bones: in the mid conc group: decrease in the number of fetuses (within tan. Variation; no dose-response relation). Incomplete ossification of sacral vertebral centers: in the mid and high dose groups: decrease in the number of fetuses (within tan. Variation; no dose-response relation; not statistically different if comparison on a per litter base).
Skeletal anomalies: (investigated: bipartite hyoid, accessory cervical rib(s), accessory lumbar rib(s), shortened rib(s), wavy rib(s), tandard-shaped vertebral centra(e), bipartite vertebral centra(e), asymmetric sternebra(e), bipartite sternebra(e) on 221; 215; 210 and 199 fetuses). Asymmetric sternebra(e): in the high-conc group: slight and significant increase in litters with fetuses displaying this anomaly. However: the relevance of this is limited by the fact it represents a minor variation (common in the strain used) and the observed incidence is still within the limits of biological variability of the rat strain used (no further data available hereon, at least not in the publication).
Accessory lumbar rib(s): mid dose group: sign.decrease in the number of fetuses with this anomaly (within boil. variation; no dose-response relation; not statistically different if comparison on a per litter base).
Effect levels (fetuses)
- Dose descriptor:
- NOAEC
- Effect level:
- 3 mg/m³ air (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: minor increase in skeletal variation (asymmetric sternebrae) at the highest dose level.
Fetal abnormalities
- Abnormalities:
- effects observed, treatment-related
- Localisation:
- skeletal: sternum
- Description (incidence and severity):
- slight increase in asymmetric sternebra(e) that is within limits of biological variability
Overall developmental toxicity
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 9 mg/m³ air (nominal)
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects as a secondary non-specific consequence of maternal toxicity effects
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Any other information on results incl. tables
Table 1 (continued from details on maternal toxic effects)
Dose level |
||||
0 mg/m3 |
1 mg/m3 |
3 mg/m3 |
9 mg/m3 |
|
No of mated dams |
26 |
26 |
25 |
25 |
No of gravid females |
25 |
26 |
25 |
23 |
No of corpora lutea (mean +/- SE) |
19.4 (2.6) |
18.9 (3.6) |
19.1 (2.3) |
19.9 (3.2) |
No of implantation sites (mean +/- SE) |
17.8 (1.5) |
7.0 (2.1) |
17.3 (3.6) |
16.7 (2.3) |
No of live foetuses per dam (mean +/- SE) |
17.0 (1.6) |
16.0 (2.1) |
16.1 (3.6) |
16.7 (2.3) |
No of postimplantation losses (mean +/- SE) |
0.9 (0.9) |
1.0 (1.2) |
1.2 (1.4) |
0.7 (0.7) |
Placental weights (mean +/- SE) |
0.57(0.05) |
0.59(0.05) |
0.60(0.08) |
0.58(0.06) |
Applicant's summary and conclusion
- Conclusions:
- Gravid rats were exposed by whole-body inhalation to clean air (control) and to 1, 3, and 9 mg/m3 monomeric MDI, respectively, for 6 hr per day from Days 6 to 15 post conception Treatment caused a dose-dependent decrease in food consumption in all substance-treated groups during exposure, returning to normal values after cessation of treatment. The lung weights in the high-dose group were significantly increased compared to the sham-treated control animals. Treatment did not influence any other maternal and/or fetal parameters investigated (maternal weight gain, number of corpora lutea, implantation sites, pre- and post implantation loss, fetal and placental weights, gross and visceral anomalies, degree of ossification), although a slight but significant increase in litters with fetuses displaying asymmetric sternebra(e) was observed after treatment with the highest dose of 9 mg/m3. Although the relevance of an increase of this minor anomaly in doses which cause toxic effects in dams (reduced food consumption, increased lung weights) is limited and the number observed is within the limits of biological variability, a substance-induced effect in the high-dose group cannot be excluded with certainty. A no embryotoxic effect level of 3 mg/m3 was determined.
- Executive summary:
The available study data for the endpoint developmental toxicity are consistent with the hypothesized MoA and based on the high reactivity of the NCO group. The hypothesized MoA predicts local effects in the lungs and no significant systemic exposure to unreacted NCO since it reacts with biological nucleophiles before being absorbed as GHS/protein adducts. No systemic toxicity was noted in the developmental toxicity study This is consistent with the observed lack of systemic toxicity in combined chronic toxicity and carcinogenicity studies on 4,4’-MDI and pMDI as well as the proposed mechanism for MDI absorption toxicokinetics.
All substances of the MDI category share similar chemical features namely that they a) all contain a significant amount of mMDI, and b) contain at least two NCO functional groups per molecule which is bound to an aromatic ring and this ring is connected to a second aromatic ring by a methylene group. It is the NCO value (driven by the bioaccessible groups on monomeric MDI and low molecular weight constituents (e.g. three-ring oligomer) which is responsible for chemical and physiological reactivity and subsequent toxicological profile. As reactive NCO groups are a common feature of all substances of the MDI category, it is predicted that these have a similar reactivity profile and a read across within the category is warranted (detailed information on the Mode of Action is available in Category Justification Document).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.